Mitogen-activated protein kinase kinase 1 (MEK1) (MEK1)

Mitogen-activated protein kinase kinase 1 (MEK1) is a dual-specificity protein kinase that acts as a key component of the MAPK/ERK signaling pathway (UniProt: Q02750). Its primary biological function is the phosphorylation and activation of Mitogen-activated protein kinase 1 (ERK2) and ERK1, which are essential for regulating cell growth, differentiation, and survival (NCBI Gene: 5604). Aberrant activation of the MEK-ERK axis is frequently observed in various cancers, often driven by mutations in upstream regulators like BRAF or RAS (PubMed: 24091325). Therapeutic targeting of MEK1 involves the use of allosteric inhibitors, such as Trametinib and Cobimetinib, which prevent the activation of ERK2 and are primarily used to treat BRAF-mutant melanoma (StatPearls: NBK551511). These inhibitors are often used in combination with BRAF inhibitors to overcome resistance and improve clinical outcomes (PubMed: 25265492). Beyond oncology, mutations in the MAP2K1 gene are associated with RASopathies, such as cardiofaciocutaneous syndrome, highlighting its essential role in normal development (NCBI Gene: 5604). Clinical management of patients on MEK inhibitors requires monitoring for specific toxicities, including dermatologic reactions and potential cardiotoxicity (StatPearls: NBK551511).

Other names

MAP2K1MAP kinase kinase 1MKK1MAPKK1ERK activator kinase 1PRKMK1

Allosteric inhibition of MEK1 and MEK2, which prevents the phosphorylation and activation of downstream ERK1 and ERK2 kinases.